Benchmark Downgrades BioLife Solutions to Hold
Benchmark analyst Robert Wasserman downgrades BioLife Solutions (NASDAQ:BLFS) from Buy to Hold.
Read original at benzingaStocks · News reference
Jefferies Downgrades BioLife Solutions to Hold, Raises Price Target to $31
Jefferies analyst Matthew Stanton downgrades BioLife Solutions (NASDAQ:BLFS) from Buy to Hold and raises the price target from $30 to $31.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 23, 2026, 6:10 PM
- Checked
- Jul 23, 2026, 6:10 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
BioLife Solns Q2 Sales $28.466M Beat $27.683M Estimate
Read original at benzinga8-K filing — BIOLIFE SOLUTIONS INC (BLFS)
Filed: 2026-08-03 AccNo: 0001628280-26-051964 Size: 270 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarHalper Sadeh LLC is Investigating Whether UTZ, BLFS, NRIM are Obtaining Fair Deals for their Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating three companies for potential securities law violations and breaches of fiduciary duties. Utz Brands is being acquired by Intersnack Group for $14.25 per share, BioLife Solutions is being sold to Repligen Corporation for $11.25 per share plus stock consideration, and Northrim BanCorp is merging with PBCO Financial Corporation. The firm is concerned that insiders may receive substantial benefits unavailable to ordinary shareholders and that transaction terms may limit competing offers.
Read original at globenewswire-inc